Hypertension augments cardiac Toll-like receptor 4 expression and activity

Hypertension Research

Volumn 34, Issue 5, 2011, Pages 551-558

  Eiler, Ruth ^a   Schmaderer, Christoph ^a   Rusai, Krisztina ^b   Kühne, Louisa ^a   Sollinger, Daniel ^a   Lahmer, Tobias ^a   Witzke, Oliver ^c   Lutz, Jens ^a   Heemann, Uwe ^a   Baumann, Marcus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

cardiac inflammation; innate immunity; L NAME; RAS inhibition; spontaneously hypertensive rat

Indexed keywords

HEPARAN SULFATE; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; RAMIPRIL; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CONTROLLED STUDY; DRUG MEGADOSE; FLUORESCENCE ACTIVATED CELL SORTING; HEART STIMULATION; HEART WEIGHT; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOMEGALY; CHEMOKINE CCL2; HEPARITIN SULFATE; HYPERTENSION; INTERLEUKIN-6; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; RAMIPRIL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79955616016     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.270     Document Type: Article

References (31)

1. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9. (Pubitemid 43049641)
2. Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166: 2018-2024. (Pubitemid 32114690)
3. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104: 271-280.
4. Chen LW, Chang WJ, Chen PH, Liu WC, Hsu CM. TLR ligand decreases mesenteric ischemia and reperfusion injury-induced gut damage through TNF-alpha signaling. Shock (Augusta, Ga) 2008; 30: 563-570.
5. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005; 68: 224-234. (Pubitemid 41428419)
6. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol 2005; 289: H1069-H1076. (Pubitemid 41208948)
7. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56: 126-134. (Pubitemid 35247809)
8. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191-F201. (Pubitemid 34654549)
9. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315: 51-57. (Pubitemid 41380497)
10. Baumann M, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 2007; 25: 207-215. (Pubitemid 44885683)
11. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88: 10045-10048. (Pubitemid 21915772)
12. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76: 514-519. (Pubitemid 39129081)
13. Wrenshall LE, Cerra FB, Singh RK, Platt JL. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J Immunol 1995; 154: 871-880.
14. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168: 5233-5239. (Pubitemid 34495991)
15. Tang AH, Brunn GJ, Cascalho M, Platt JL. Pivotal advance: endogenous pathway to SIRS, sepsis, and related conditions. J Leukoc Biol 2007; 82: 282-285. (Pubitemid 47230638)
16. Zemancikova A, Torok J. Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. Physiol Res 2009; 58: 921-925.
17. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG, Rudolph AE. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H1775-H1784. (Pubitemid 35217010)
18. Bergman MR, Kao RH, McCune SA, Holycross BJ. Myocardial tumor necrosis factoralpha secretion in hypertensive and heart failure-prone rats. Am J Physiol 1999; 277(2 Pt 2): H543-H550. (Pubitemid 29415967)
19. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47: 467-474. (Pubitemid 43740292)
20. Otsui K, Inoue N, Kobayashi S, Shiraki R, Honjo T, Takahashi M, Hirata K, Kawashima S, Yokoyama M. Enhanced expression of TLR4 in smooth muscle cells in human atherosclerotic coronary arteries. Heart Vessels 2007; 22: 416-422. (Pubitemid 350201439)
21. Cruzado MC, Risler NR, Miatello RM, Yao G, Schiffrin EL, Touyz RM. Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation. Am J Hypertens 2005; 18: 81-87. (Pubitemid 40187353)
22. Lee SK, Arunkumar S, Sirajudeen KN, Singh HJ. Glutathione system in young spontaneously hypertensive rats. J Physiol Biochem 2010; 66: 321-327.
23. Kassan M, Montero MJ, Sevilla MA. Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats. Br J Pharmacol 2009; 158: 541-547.
24. Kee HJ, Eom GH, Joung H, Shin S, Kim JR, Cho YK, Choe N, Sim BW, Jo D, Jeong MH, Kim KK, Seo JS, Kook H. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res 2008; 103: 1259-1269.
25. Niizeki T, Takeishi Y, Watanabe T, Nitobe J, Miyashita T, Miyamoto T, Kitahara T, Suzuki S, Sasaki T, Bilim O, Ishino M, Kubota I. Relation of serum heat shock protein 60 level to severity and prognosis in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2008; 102: 606-610.
26. Lv J, Jia R, Yang D, Zhu J, Ding G. Candesartan attenuates angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 2009; 380: 81-86.
27. Ji YY, Wang ZD, Liu JT, Liu N. [Inhibitory effect of fenofibrate on angiotensin II-induced toll-like receptor 4 expression, myeloperoxidase activity and expression in RAW264.7 cells]. Yao Xue Xue Bao 2009; 44: 462-467.
28. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893-900.
29. Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, Burns K, Riederer BM, Akira S, Calandra T. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009; 106: 2348-2352.
30. Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, Kosco-Vilbois M, Wagner H, Kirschning CJ, Ulevitch R, Elson G. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007; 179: 6107-6114.
31. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005; 174: 6416-6423. (Pubitemid 40663835)